# Kindwise

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kindwise

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.whkdws.com
- Total disclosed funding: $28M
- Latest round: Series B (Dec 5, 2024)
- Investors on record: 4

## About

Based in Wuhan, China, and founded in 2018, Kindwise operates as a biological diagnosis and treatment service provider, focusing on the innovative products for diagnosis and treatment of gynaecological tumours. It is a National High-Tech Enterprise. The chairman of the board, Ding Ma, is an academician of the Chinese Academy of Engineering. It has cooperated with Wuhan Central Hospital, Guangdong Provincial Women and Children's Health Hospital, Shenzhen Second People's Hospital and the Third Affiliated Hospital of Zhengzhou University and other hospitals. In December 2024, Kindwise raised approximately CNY 200 million in series B funding.

Kindwise specializes in innovative diagnostic solutions and therapeutic products for gynaecological oncology. Their core offerings include technologies for HPV detection and typing, as well as early diagnostic kits for breast cancer and cervical cancer treatments. The company's flagship products, such as the HPV typing and integrated detection kits, aim to enhance precision in diagnosis and improve patient outcomes by facilitating early intervention. The integration of high-throughput sequencing technologies, such as those from ILLUMINA, further strengthens their product line-up by enabling comprehensive genomic analysis.

The company generates revenue by providing biological diagnosis and treatment services.

The company will use the series B funding for the clinical development and market expansion of the company's products in the field of gynaecological tumour diagnosis and treatment.

## Funding rounds

- Series B, Dec 5, 2024, $28M — Hubei Science Technology Investment Group, Wuhan Hi-tech Holding Group, Hubei Hongtai Group, FIRHealth Capital

## Investors

- Hubei Science Technology Investment Group — Series B
- Wuhan Hi-tech Holding Group — Series B
- Hubei Hongtai Group — Series B
- FIRHealth Capital (https://capitalatlas.ai/funds/firhealth-capital) — Series B